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Extending the Benefits of Indicated Prevention
to Improve Outcomes of First-Episode Psychosis
Outcomes of psychotic disorders are associatedwith
highpersonal, familiar, societal, andclinicalburden.Thus,
there is an urgent clinical and societal need for improv-
ing outcomes of psychosis. Research findings from the
past2decadeshaveopenednewopportunities forame-
liorating outcomes of psychosis through indicated pri-
mary prevention in individuals at clinical high risk for
psychosis (CHR-P). Indicated primary prevention in in-
dividuals at CHR-P can result in (1) delayed or pre-
vented onset of first episode. Furthermore, secondary
prevention in individuals at CHR-P who will later de-
velop the disorder may also (2) reduce the duration of
untreated psychosis, hospital admission, and compul-
sory admission1 and (3) improve early detection and
ameliorate the severity of first-episode cases.1
To optimize these benefits, available research has
mostly focused on improving the prognostic accuracy
and the effectiveness of preventive treatments for in-
dividuals atCHR-P.However, the firstmajorbarrier is the
difficulty of identifying all the individualswhomay later
developpsychosis. Recent evidence suggests that even
well-established CHR-P services with more than 1 de-
cade of implementation history can only identify very
few individuals (approximately5%)whowill goontode-
velop a first episode of psychosis in secondary mental
health care.2 Because most individuals (approximately
95%)whowill develop a first episode are not currently
benefiting from indicated prevention, there is a press-
ing andurgentneed toenhanceour ability todetect the
individuals who are at risk. Identifying at-risk individu-
alswhowill laterdeveloppsychosis (truepositives) ispar-
ticularly challenging. I suggest specific and differential
strategies each targeting secondarymental health care,
primary care, or the community.
Secondarymentalhealthcare isusually themost fre-
quent source of referrals to CHR-P services.3 Further-
more, the recruitment of individuals for CHR-P assess-
ment through secondary mental health services is
associated with the highest pretest risk of developing
psychosis.4 In fact, these individualsare likely tohaveac-
cumulated several risk factors for psychosis, such as af-
fective comorbidities, substance abuse, and social
deprivation.5 In line with these research findings, cur-
rent clinical guidelines (eg, the European Psychiatry As-
sociation) specifically recommend that CHR-P assess-
ment should only be offered to individuals who are
“alreadydistressedbymentalproblemsandseekinghelp
for them.”6 However, because referral is currentlymade
only on suspicion of psychosis risk, recruitment strate-
gies insecondarymentalhealthcareareopportunisticand
idiosyncratic, andmost individuals (approximately95%)
who will later develop psychosis currently remain
undetected.2 Apractical solutionmaybe to use recently
developed individualized risk calculators. These calcula-
tors are basedon simple sociodemographic and transdi-
agnostic clinical variables that can be easily accessed in
clinical routine(http://www.psychosis-risk.net).2Theuse
of these tools shows clear clinical advantages compared
with other identification strategies, such as CHR-P
assessment only on suspicion of psychosis risk (only
approximately 5% of cases detected) or systematic
assessmentofall individualsunder thesecondarymental
health care (logistically and financially not sustainable).
The next generation of research will need to test the
pragmatic utility of similar tools to substantially improve
the proportion of individuals developing psychosis who
are accessing secondarymental health care during their
at-risk phase and who may be signposted for CHR-P
assessment and care.
The second most frequent source of referrals to
CHR-P services is primary care, in particular general
practitioners.3 Information campaigns and increased
liaison between primary and secondary care may im-
prove the detection of people at risk of developing
psychosis.7However, individuals recruited throughpri-
mary care are likely to have accumulated less risk fac-
tors for psychosis compared with those recruited
through secondary mental health care5 and therefore
have an intermediate pretest risk for psychosis.4 This
wouldmean thateven if theproportionof referrals from
primary care to CHR-P services is improved, the prog-
nostic accuracy of the CHR-P instrument per se would
be lower, with a reduced transition to psychosis over
time. A solution may be to adopt sequential screening
methods that allow some risk enrichment during the
recruitment of samples undergoing CHR-P assess-
ment.Forexample,a large-scaleprospectivestudy8con-
ducted in 2017 among young adults, adolescents, and
childrenaccessingpediatricphysicalhealthclinics inhos-
pital settings used a prescreening assessment for psy-
chotic experiences that included computerized self-
ratedquestions,supplementedwithsemi-structuredand
structured questions. Individuals passing the initial fil-
ter were then provided a full CHR-P assessment.8 Such
anapproachyieldedclinicallymeaningful resultsandmay
be replicated in primary care, constituting the basis for
an improved detection of individuals at risk. However,
thisapproachrequiresclinical andresearchresources for
the initial screening. Future researchmay complement
such a strategywith theuseof individualized risk calcu-
lators that are specifically developed and validated in
primary care.
The third sourceof referrals toCHR-Pservices is the
general community. Systematically screening individu-
als fromthecommunitywithaCHR-Passessment is cur-
rently not supported by clinical guidelines on several
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grounds. Individuals not underprimaryor secondarymental health
care are likely to have accumulated only a few risk factors for psy-
chosis compared with those recruited through primary or second-
ary care.5 In fact, they show the lowest pretest risk for psychosis,4
especially if no help-seeking behavior is observed. Because of this,
the prognostic accuracy of CHR-P instruments in these individuals
isparticularly low,withdebatableprognosticutility.3Becauseofsuch
low risk enrichment, standalone outreach campaigns targeting the
wide community are not a viable approach to identify at-risk indi-
viduals undergoingCHR-P assessment.Heavily recruiting individu-
als fromthecommunitymayalso lead to reducedpower in random-
izedclinical trials ofpreventive interventionsand thereforeproduce
negative research findings.9 These challenges may only be miti-
gatedbythe implementationof front-lineprimarycarementalhealth
models for youth to facilitate the recruitmentof youngpeople from
the school and community (eg, https://www.headspace.org.au).
Future research strategies may test the use of e-health technolo-
gies integrated with social media as gateways to these mental
health models for non–help-seeking youth at risk of psychosis in
the community.
On amore conceptual level, the fact that only aminority of in-
dividualswhowill actually developpsychosis is usually detectedby
CHR-P services augments concerns on the epidemiological invalid-
ity of the paradigm and on the questionable representativeness of
theCHR-Pasa referenceriskstageprecedingthe firstepisodeofpsy-
chosis.Forexample, itmaybepossible that individualsatCHR-Pwho
will laterdeveloppsychosis representadistinctivehelp-seekingsub-
group with different clinical characteristics and outcomes com-
paredwith standard first-episode samples. Extensiveneurobiologi-
cal research has deeply investigated CHR-P samples, holding the
assumption that the observed alterations would represent proto-
typical features preceding the onset of psychosis. Such an assump-
tion is not fully substantiated. Because individuals at CHR-P devel-
opingpsychosis representonlya tinyminorityof first-episodecases,
generalizability of neurobiological alterations observed in the pub-
lishedstudies isundetermined.Theseconsiderationsmayaffecton-
going large-scale international CHR-P consortia predicated on the
ultimategoal of developing clinical tools topredict theonsetofpsy-
chosis from an at-risk stage.
In summary, the CHR-P paradigm has provided unprec-
edented knowledge into the onset of psychosis, allowing the first-
ever clinical implementationof indicatedprimarypreventionofpsy-
chosis. At the same time, itsmajorweaknesses arenowclearer, and
the future of the paradigm ismore uncertain than it was 2 decades
ago. By acknowledging these limitations, I hope to constructively
stimulate the next generation of research. I feel that only by priori-
tizing research into the recruitment process of CHR-P samples can
we defend its epidemiological validity and in turn extend the ben-
efits of indicated prevention to improve outcomes of first-episode
psychosis.
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